












Example	X	R ⁴
C	OCF ₂ H	
F	OCH ₃	
G	CH ₃	
I	OCH ₃	
J	OCF ₃	
L	Cl	
O	Cl	
Q	CH ₃	
Z	OCH ₃	
AA	OCH ₃	C ₃ H ₇
AB	CF ₃	
AC	CF ₃	











C₂
cont.

C

Example	X	R ⁴
AF	CF ₃	
AI	CF ₃	
AK	Cl	
AM	Cl	
AQ	Cl	
AU	Cl	
AX	Cl	C ₃ H ₇
BA	OCF ₃	
BB	OCF ₃	
BC	OCF ₃	
BG	OCH ₃	


C2
cont.

C

Example	X	R ⁴
BX	OCH ₃	
CB	CH ₃	
CD	Cl	
CE	Cl	
CW	OH	
CX	OH	
DA	OCF ₂ H	
FR	H	
FS	H	
FT	H	


C2
cont.

e




Example	X	R ⁴
FW	H	

Please cancel claim 7 without prejudice and substitute cancelled claim 7 with new claim 59 therefor.










59. (New) The compound according to Claim 1 of the formula



or a pharmaceutically acceptable salt or solvate thereof,
wherein X and R⁴ are as shown in the table below:

Example	X	R ⁴
R	CF ₃	
S	Cl	
W	Cl	

C²
cont.

Example	X	R ⁴
AE	CF ₃	
AG	CF ₃	
AH	CF ₃	
AR	Cl	
AS	Cl	
AZ	Cl	
BD	OCF ₃	
BJ	OCH ₃	
BZ	CH ₃	

C


C2 cont.

Example	X	R ⁴
CA	CH ₃	
FY	H	
FZ	H	
GI	Cl	
GJ	OCH ₃	
GL	OH	
GM	OCH(CH ₃) ₂	
GN		

Please cancel claim 8 without prejudice and substitute cancelled claim 8 with new claim 60 therefor.

51-60. (New) The compound according to Claim 1 of the formula














T, 1132



or a pharmaceutically acceptable salt or solvate thereof;
wherein X, R¹ and R⁴ are as shown in the table below:

Example	X	R ¹	R ⁴
A	OCH ₃	CH ₃	
C	OCF ₂ H	CH ₃	
G	CH ₃	CH ₃	
L	Cl	CH ₃	
R	CF ₃	CF ₃	
S	Cl	CF ₃	
AB	CF ₃	CH ₃	










C

Example	X	R ¹	R ⁴
AT	Cl	N(CH ₃) ₂	
BA	OCF ₃	CH ₃	
BD	OCF ₃	CF ₃	
BZ	CH ₃	CF ₃	
CD	Cl	CH ₃	
FS	H	CH ₃	
FY	H	CF ₃	
XXX		CF ₃	
XXXII	CN	CF ₃	
XXXIII	NH ₂	CF ₃	
XXXIV		CF ₃	

C²
cont.


e

C² could

Example	X	R ¹	R ⁴
XXXIX	-CONH ₂	CF ₃	
XXXX	-OCH ₃	CF ₃	
XXXXI	-OH	CF ₃	
XXXXII		CF ₃	
XXXXIII		CF ₃	
XXXXIV	H ₃ C-CH ₂ -O-	CF ₃	
XXXXV	H ₃ C-O-CH ₂ -CH ₂ -O-	CF ₃	

Please amend Claims 1-3, 31, 39-41, 43-49, 51-53, and 55-57 to read as follows.

1. A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of H, alkyl, haloC₁-C₆ alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, -N(R²)₂, -N(R²)aryl, unsubstituted aryl and aryl substituted with one to three X, wherein each R² can be the same or different and is independently selected when there are more than one R² present;

R^2 is selected from the group consisting of H and C₁-C₆ alkyl;

R^3 is 1-3 substituents selected from the group consisting of H, C₁-C₆ alkyl, Cl, F, CF₃, OCF₂H, OCF₃, OH and C₁-C₆ alkoxy, wherein R³ can be the same or different and is independently selected when there are more than one R³ present;

C³ cont.
 R^4 is selected from the group consisting of H, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, N(R²)₂, or N(R²)aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, and phenyl, optionally substituted with one to three X, wherein X can be the same or different and is independently selected when there are more than one X present;

R^5 is H or C₁-C₆ alkyl;

R^6 is H or C₁-C₆ alkyl; or

R^5 and R^6 taken together with the carbon atom to which they are attached form a carbonyl group;

L^1 is -SO₂-, -SO-, or -S-;

L^2 is -SO₂-, -SO-, or -S-;

X is selected from the group consisting of H, halogen, CF₃, CN, OCF₂H, OCF₂CF₃, OCF₃, OR², C₁-C₆ alkyl, cycloalkyl, cycloalkoxy, C₁-C₆ alkoxy, alkoxyC₁-C₆ alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO₂R², -COOR², -CON(R²)₂, N(R²)₂, and NR²aryl, wherein X can be the same or different, and is independently selected when there are more than one X present;

Y is a covalent bond, -CH₂-, -SO₂-, or -C(O)-;

Z is a covalent bond, -CH₂-, -SO₂- or -C(O)-; or

Y, R¹, Z and R² can be taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl; with the following provisos:

when R² is H, Z cannot be -S(O)-, -SO₂-, or -C(O)-; and

when Y is a covalent bond, R¹ cannot form a N-N bond with the nitrogen atom.

2. A compound according to claim 1 wherein

L¹ is -SO₂-, -S- or -S(O)-;

L² is -SO₂-;

R¹ is H, -CH₃NH₂, -CH₂CF₃, -NHC₃H₇, -NHC₂H₆, -NHC₄H₉, C₁-C₆ alkyl,

-CF₃, -CH(CH₂)₂, thiophenyl, morpholinyl, cyclopropyl, benzyl, naphthyl, -C(CH₃)₃, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or N(CH₃)₂;

R² is H or CH₃;

R³ is OH;

R⁴ is thiophenyl, alkoxy, cyclohexyl, phenyl, tolyl, C₃H₇, methoxyphenyl, or CH₃; all of the above optionally substituted with one to three X, wherein X can be the same or different and are independently selected when there are more than one X present;

R⁵ and R⁶ are independently H or CH₃;

Y is a covalent bond, -SO₂- or -C(O)-;

Z is a covalent bond; or

R¹, Y, R² and Z taken together with the nitrogen atom form a morpholinyl group.

3. The compound according to claim 2 wherein

X is halogen, OH, or cyclopropyl;

R³ is OH;

R⁵ and R⁶ are independently H or CH₃;

X is H, halogen, CF₃, OCH₃, OH, OCF₃, OCF₂H, CH₃ or C₁-C₆ cycloalkyl;

Y is a covalent bond;

Z is -SO₂- or -C(O)-;

L¹ is -SO₂-;

L² is -SO₂-;

R¹ is CH₃ or CF₃; and

R⁴ is phenyl, said phenyl optionally substituted with one to three substituents selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, OH, CF₃ and halogen, wherein said substituents can be the same or different and are independently selected when there are more than one substituent.

C3
condensed

C4

20/39

31. A pharmaceutical composition comprising one or more compounds according to claim 58 and one or more pharmaceutically acceptable carriers.

C5

20/25

25/24

35. The method of claim 34 wherein the condition or disease treated is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis and chronic obstructive pulmonary disease.

C6

20/40

39. A method of treating rheumatoid arthritis which comprises co-administration one or more compounds selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound, a PDE IV inhibitor or other classes of compounds indicated for the treatment of rheumatoid arthritis and one or more compounds of Claim 58.

29/31

28/28

40. The method of Claim 38 wherein the COX-2 inhibitor is celecoxib or rofecoxib, the COX-1 inhibitor is piroxicam, the immunosuppressive is

C

methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

C6
conceded

~~41~~

~~40~~

41. The method of Claim 39 wherein the COX-2 inhibitor is celecoxib or rofecoxib, the COX-1 inhibitor is piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

~~42~~

43. A composition for treating rheumatoid arthritis which comprises one or more compounds selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and one or more compounds of Claim 38.

C7

~~31~~

~~30~~

44. The composition of Claim 42 wherein the COX-2 inhibitor is celecoxib or rofecoxib, the COX-1 inhibitor is piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

~~43~~

~~42~~

45. The composition of Claim 43 wherein the COX-2 inhibitor is celecoxib or rofecoxib, the COX-1 inhibitor is piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

C

32 ~~37~~

46. A method of treating multiple sclerosis which comprises co-administration one or more compounds selected from interferon beta-1a, interferon beta-1b, glatiramer acetate or other compounds indicated for the treatment of multiple sclerosis and one or more compounds of Claim 1.

44 ~~58~~

47. A method of treating multiple sclerosis which comprises co-administration one or more compounds selected from interferon beta-1a, interferon beta-1b, glatiramer acetate or other compounds indicated for the treatment of multiple sclerosis and one or more compounds of Claim 58.

38

C1
considered.

33 ~~39~~

48. A composition for treating multiple sclerosis which comprises one or more compounds selected from interferon beta-1a, interferon beta-1b, glatiramer acetate or other compounds indicated for the treatment of multiple sclerosis and one or more compounds of Claim 1.

45 ~~40~~

49. A composition for treating multiple sclerosis which comprises one or more compounds selected from interferon beta-1a, interferon beta-1b, glatiramer acetate or other compounds indicated for the treatment of multiple sclerosis and one or more compounds of Claim 58.

38

46 ~~42~~

51. A method of treating psoriasis which comprises co-administration of one or more compounds selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and one or more compounds of Claim 58.

38

C2

C

35 ~~43~~

34 ~~41~~

52. The method of Claim 50 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

C8
conced.

47 ~~44~~

46 ~~42~~

53. The method of Claim 51 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

48 ~~46~~

55. A composition for treating psoriasis which comprises one or more compounds selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and one or more compounds of Claim 58.

38 ~~40~~

37 ~~44~~

36 ~~45~~

56. The composition of Claim 54 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is etanercept or infliximab.

49 ~~48~~

48 ~~46~~

57. The composition of Claim 55 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound etanercept or infliximab.

REMARKS

Applicants are filing this response within three months of the Office Acton dated January 22, 2003. Accordingly, this response is being filed timely, and no fee is due.

C